Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Daiichi Sankyo
Fish and Richardson
US Department of Justice

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,020,311

« Back to Dashboard

Summary for Patent: 6,020,311

Title: GRF analogs with increased biological potency
Abstract:The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.
Inventor(s): Brazeau; Paul (Montreal, CA), Gravel; Denis (St-Lambert, CA)
Assignee: Theratechnologies, Inc. (Montreal, CA)
Application Number:09/148,982
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Use;

No matches for this query

International Patent Family for Patent: 6,020,311

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia5500799► Subscribe
Brazil9608799► Subscribe
Brazil9913515► Subscribe
Canada2222068► Subscribe
Canada2342070► Subscribe
Germany1109909► Subscribe
Germany69614849► Subscribe
Germany69928677► Subscribe
Denmark0828758► Subscribe
European Patent Office0828758► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cantor Fitzgerald
Fish and Richardson
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: